To better understand cancer dependencies, we sought to characterize the co-occurring genomic alterations of class I, class II, and class III BRAF variants in NSCLC using data available in the cBioPortal clinico-genomic database distinct from our institutional cohort (Class I n = 113, Class II n = 97, Class III n = 132)18,19. This evidence concerns the gene BRAF and cancer.